Search Courses

Course Catalog

Miscellaneous Courses
  • Course Code
    AVIR2021-1
    Available Until
    3/30/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    9:45a Presidential WelcomeRennie Mohabir, MBA, RT(R) (no CE)
    10:00a Evolution not Revolution - Indispensable CARE - Dr Janice Newsome, Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access - Dr Mark Lessne
    11:40a Covid-19 - Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization - Dr Kavi Devulapalli
    2:00p PAD Inflow - Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE)
    2:50p PE Interventions - Dr Charles Ritchie
    3:45p Combating Burnout - Dr Agnes Solberg
    4:20p Radiation Safety - Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-10
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-11
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-12
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-13
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke - Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-14
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-15
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-16
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-17
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-18
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke    Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

  • Course Code
    AVIR2021-19
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-2
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-20
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-21
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-22
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-23
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-24
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-25
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-26
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-27
    Available Until
    3/22/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 3 - MONDAY MARCH 22nd
    10:00a    Trauma Intervention - Dr Barbara Hamilton
    10:50a    Passion Projects and Burnout - Dr Aaron Fritts
    11:20a    Thermal Ablations - Dr Charles Martin
    11:55a    Advanced IVCF Filter Retrieval - Dr Peter Stibbs
    1:20p    BREAK    
    1:30p    10,000 foot Perspective on Embolization - Dr Ziv Haskal
    2:15p    Innovations in Peds IR - Dr John Racadio
    2:55p    Renal Ablations - Dr Robert Dixon
    3:30p    Artificial Intelligence in the IR Lab - Dr Rajesh Shah
    4:20p    IR Coding - Jennifer Eklund RT(R)(CV)(M) CIRCC

  • Course Code
    AVIR2021-3
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-4
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE)
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-5
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-6
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-7
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-8
    Available Until
    3/20/2023
    Course Type
    Annual Meeting
    CEUs
    0.50

    Day 1 - March 20, 2021

    10:00a Evolution not Revolution - Indispensable CARE by Dr Janice Newsome - Shari Ulman Gold Medal Lecture Recipient, sponsored by Medtronic
    10:50a Complex Hemodialysis Access by Dr Mark Lessne
    11:40a Covid-19 by Dr Tania Bubb
    12:30p BREAK
    1:00p Prostate Artery Embolization by Dr Kavi Devulapalli
    2:00p PAD Inflow by Dr Kumar Madassery
    2:40p Medtronic Presentation (no CE
    2:50p PE Interventions by Dr Charles Ritchie
    3:45p Combating Burnout by Dr Agnes Solberg
    4:20p Radiation Safety by Dr Lawrence Dauer
    5:00p Business Meeting/Awards (no CE)

  • Course Code
    AVIR2021-9
    Available Until
    3/21/2023
    Course Type
    Annual Meeting
    CEUs
    1.00

    Day 2 - SUNDAY MARCH 21st
    10:00a    Endovascular Therapy for Infrapopliteal Disease - Dr John Winscott
    11:00a    Medtronic Commercial (No CE)    
    11:10a    Global Health Panel Talk - Drs Azza, Laage-Gaupp, Dixon, Newsome, Mbuguje, Rukundo
    12:00p    Venous Interventions, SVC Occlusions - Dr Gail Peters
    12:30p    Dialysis Access Interventions - Dr Peter Bream
    1:10p    BREAK    
    1:30p    Stroke - Dr David Miller
    2:30p    Intracranial Aneurysms - Dr Rabih Tawk
    3:05p    Management of Carotid Disease - Dr Rabih Tawk
    4:00p    Y90 Radioembolization: Technique and Outcomes - Dr Ahmed Kamel Abdelaal
    4:45p    IR Social Media: What, Where, When and Why - Dr AJ Gunn
    5:15p    Portal Vein Thrombectomy - Dr Alex Wallace

Miscellaneous Courses
  • Course Code
    AVIR-DJR 32
    Available Until
    8/23/2021
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    The Society of Interventional Radiology (SIR) considers the use of catheter directed therapy (CDT) or thrombolysis to be an acceptable treatment option for carefully selected patients with massive (ie, high-risk) pulmonary embolism (PE) involving the proximal pulmonary arterial vasculature, in accordance with multidisciplinary guidelines (1–4). SIR defines acute proximal PE as new main or lobar emboli identified on radiographic imaging within 14 days of PE symptoms. In addition, SIR encourages the investigative use of CDT and new endovascular techniques in prospective outcomes studies and clinical trials, with particular attention to patients with acute submassive (ie, intermediate-risk) PE.

  • Course Code
    AVIR-DJR 38
    Available Until
    3/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    In a single-arm, nonrandomized, retrospective case-control study, 39 patients (mean age, 44 y) who underwent elective outpatient uterine artery embolization (UAE) with the use of superior hypogastric nerve block (SNHB) for pain control over a period of 3 years were identified. Technical success of SNHB was 87%. Of the 34 patients who received SNHB, 97% did not need a patient-controlled analgesia pump. The median opioid requirement for the 17 patients who needed opioid agents was 7.5 morphine milligram equivalents (interquartile range [IQR], 10). The median length of stay was 2.2 hours (IQR, 1.7 h). SHNB offers a safe and effective intervention that significantly reduces pain and the need for opiate agents and allows same-day discharge after UAE.

  • Course Code
    AVIR-DJR33
    Available Until
    11/9/2021
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    There is continuing debate among physicians, nurses, and federal regulatory agencies regarding the correct position for the tip of a central venous catheter. The traditional approach has been to place the catheter tip within the superior vena cava. However, many interventionalists believe that the performance and durability of the catheter will be improved by positioning the catheter tip within the upper right atrium. Recently, this variability in clinical practice has become an increasingly divisive issue among physicians who insert these catheters and nurses who use them. This article is intended to elucidate the controversial issues and provide a brief review of the extensive literature on this important topic.

  • Course Code
    AVIR-DJR34
    Available Until
    11/9/2021
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    ABSTRACT

    Eight patients with giant prostatic enlargement > 200 mL and lower urinary tract symptoms who underwent bilateral prostatic artery embolization (PAE) were reviewed. Mean prostate volume decreased from 318.2 mL to 212.2 mL (P < .01). At 5-month mean follow- up, International Prostate Symptom Score decreased by 16.7 points (P < .05), and urinary quality of life improved by 3.0 points (P < .01). Three of 4 catheter-dependent patients no longer needed catheterization after the procedure. No major complications were encountered. Preliminary results suggest PAE is safe and effective in patients with giant prostatic enlargement > 200 mL.

    page1image12384page1image12544

  • Course Code
    AVIR-DJR35
    Available Until
    11/11/2021
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Percutaneous endovascular interventions have been widely used and proven as the standard of care in the management of dysfunctional dialysis access and as an effective alternative compared with similar surgical interventions. This document provides an update on key topics relevant to endovascular management of thrombosed or dysfunctional dialysis access since the first SIR guidelines published in 2003.

  • Course Code
    AVIR-DJR37
    Available Until
    2/15/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose

    To present final, 2-year results of a randomized trial comparing paclitaxel-coated vs uncoated balloon angioplasty following vessel preparation with ultra–high-pressure percutaneous transluminal angioplasty (PTA) in hemodialysis arteriovenous fistulae (AVFs).

    Materials and Methods

    Twenty-three sites enrolled 285 subjects with dysfunctional AVFs located in the arm. Before 1:1 randomization, successful vessel preparation was achieved (full waist effacement, < 30% residual stenosis). Follow-up was clinically driven except for a 6-month office visit.

    Results

    Ninety-six of 141 subjects in the drug-coated balloon (DCB) arm and 111 of 144 in the control arm completed the study. Target lesion primary patency (TLPP) rates for the DCB and control groups were 58% ± 4 vs 46% ± 4 (P = .02) at 9 months, 44% ± 5 vs 36% ± 4 (P = .04) at 12 months, 34% ± 5 vs 28% ± 4 (P = .06) at 18 months, and 27% ± 4 vs 24% ± 4 (P = .09) at 24 months, respectively. Mean time to TLPP event for subjects with an event was longer for DCBs (322 vs 207 d; P < .0001). Fewer interventions were needed to maintain target lesion patency in the DCB group at 9 months (P = .02) but not at 12 (P = .08), 18 (P = .13), or 24 months (P = .19). The noninferiority safety target was met at all intervals (P < .01). Mortality did not differ between groups (P = .27). Post hoc analyses showed equivalent DCB effect in all subgroups.

    Conclusions

    Two-year results demonstrate long-term safety and variable efficacy of DCB angioplasty in AVFs.

     

  • Course Code
    AVIR-DJR39
    Available Until
    4/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Image-guided percutaneous drainage or aspiration of abscesses and abnormal fluid collections (PDAFC) has become the diagnostic and therapeutic treatment of choice for a wide variety of fluid collections. The procedures have resulted in reduced morbidity and mortality and have helped to reduce length of hospital stay and hospital costs (1–18). This Society of Interventional Radiology (SIR) Quality Improvement (QI) Guideline outlines the specifications and principles for performing high-quality PDAFC.

  • Course Code
    AVIR-DJR40
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To determine if magnification spot radiographs acquired before attempting inferior vena cava (IVC) filter removal have value in the assessment for filter fractures. 

    Materials and Methods: A retrospective review of complex IVC filter removals performed at a tertiary referral center from October 2015 to May 2017 was performed. Magnification spot radiographs (frontal and at least 2 oblique views) were obtained with the fluoroscopic unit in the procedure suite prior to venous access for filter removal. Patients were included in the study if a computed tomography (CT) scan of the abdomen/pelvis before filter removal was available. Ninety-six patients (47 women and 49 men) were included. Most removed filters were the Recovery/G2/G2X/Eclipse/Meridian (n ¼ 28), the Günther Tulip (n ¼ 26), and the Celect/Celect Platinum (n ¼ 22). Blinded review of the pre-procedural CT scans and spot radiographs for the presence of filter fractures was performed by 2 interventional radiologists. Accuracy of each modality was assessed using the status of the explanted filter as the gold standard. Agreement between the 2 readers was assessed with the kappa statistic. 

    Results: Fractures were present in 27 explanted filters (28%). Accuracy of CT was 88% and 68% for readers 1 and 2, respectively, which increased to 98% and 97% with magnification spot radiographs. The kappa statistic was 0.12 for CT and 0.97 for spot radiographs. 

    Conclusions: Magnification spot radiographs acquired before attempting IVC filter removal improve detection of filter fractures and agreement among interventional radiologists. Therefore, these should be performed routinely to allow for optimal treatment planning.

  • Course Code
    AVIR-DJR41
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Although a snare is the commonly used device for antegrade double J (DJ) stent removal, there are some cases in which DJ stent removal using only a snare is particularly difficult. In the present study, an unfavorable positioning of the proximal DJ stent tip and tip embeddedness were significantly associated with a simple snare technique failure; thus, present the modified snare technique to overcome the simple snare technique failure. By applying these 2 techniques together, we can increase the overall technical success rate up to 97% (196/202). The modified snare technique is safe and effective in cases of simple snare technique failure.

  • Course Code
    AVIR-DJR42
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To evaluate the rate and risk factors for hemorrhage in patients undergoing real-time, ultrasound-guided paracentesis by radiologists without correction of coagulopathy. Materials and Methods: This was a retrospective study of all patients who underwent real-time, ultrasound-guided paracentesis at a single institution over a 2-year period. In total, 3116 paracentesis procedures were performed: 757 (24%) inpatients and 2,359 (76%) outpatients. Ninety-five percent of patients had a diagnosis of cirrhosis. Mean patient age was 56.6 years. Mean international normalized ratio (INR) was 1.6; INR was > 2 in 437 (14%) of cases. Mean platelet count was 122 x 103 /μL; platelet count was < 50 x 103 /μL in 368 (12%) of patients. Seven hundred seven (23%) patients were dialysis dependent. Patients were followed for 2 weeks after paracentesis to assess for hemorrhage requiring transfusion or rescue angiogram/embolization. Univariate analysis was performed to determine risk factors for hemorrhage. Blood product and cost saving analysis were performed. Results: Significant post-paracentesis hemorrhage occurred in 6 (0.19%) patients, and only 1 patient required an angiogram with embolization. No predictors of post-procedure bleeding were found, including INR and platelet count. Transfusion of 1125 units of fresh frozen plasma and 366 units of platelets were avoided, for a transfusion-associated cost savings of $816,000. Conclusions: Without correction of coagulation abnormalities with prophylactic blood product transfusion, post-procedural hemorrhage is very rare when paracentesis is performed with real-time ultrasound guidance by radiologists.

  • Course Code
    AVIR-DJR43
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Single-step pull-type gastrostomy tube (PGT) placement is a method involving gastric puncture with a curved 18-gauge trocar needle
    allowing retrograde cannulation of the gastroesophageal junction without use of a sheath or snare. This retrospective review of 102
    patients who underwent single-step PGT placement demonstrated 91% success in advancing the wire up the esophagus using only the
    curved trocar. Successful placement of a gastrostomy tube was 100%. Two major and 2 minor complications occurred within 30 days, all
    unrelated to the single-step technique. Mean fluoroscopy time for all patients was 5.1 min (range, 1.5–19.2 min). Single-step PGT
    placement is an effective, safe, fast, and equipment-sparing method for gastrostomy placement.

  • Course Code
    AVIR-DJR44
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To analyze technique, outcomes, and complications of a large series of pediatric percutaneous nephrostomy (PCN) procedures performed at 4 tertiary pediatric centers. Materials and Methods: Retrospective multicenter study of PCNs performed during an 11-year period. Six hundred seventy-five PCNs were performed on 441 patients (median age: 4 y, range: 1 d–18 y, median weight: 17 kg, range: 0.7–112 kg); 31% were younger than 1 year. The most frequent indications for PCN procedures included hydronephrosis (57%), calculus (14%), and infection (12%). Forty-five percent of patients had severe and 32% had moderate hydronephrosis. Results: Technical success was 99% (n ¼ 668); 7 failures occurred from lost access, during tract dilatation (n ¼ 5) and during staghorn calculi without dilatation (n ¼ 2). General anesthesia was used in 73% of procedures. Combined ultrasound and fluoroscopy was used in 98% of procedures. Of the 668 procedures, 561 (84%) were primary nephrostomy insertions, and 107 (16%) were a variety of exchanges (secondary catheter insertions). Twenty-four of 675 (4%) were transplanted kidneys. Access sites included lower (47%), mid (28%), and upper (12%) poles and pelvis (11%). Catheters were predominantly 7-8 French (n ¼ 352). The mean catheter dwell time was 25 days (0–220 d). Total primary catheter days were 14,482, with an additional 2,241 days after secondary procedures. Follow-up in 653/668 (98%) procedures documented elective removal (79%) and salvage procedures (21%), which included wire exchange (8.7%), nephroureteral stent/catheter conversion (8.8%), and tube upsizing (3.5%). Periprocedural complications occurred in 30/668 (4.5%) procedures: 1 major (0.1%) self-limiting hematuria requiring transfusion and 29 (4.4%) minor complications. Conclusions: PCN is safe and successful in children of all ages, with few major complications. PCN in children is associated with specific technical challenges and requires ongoing management tailored to the very young to achieve good outcomes.

  • Course Code
    AVIR-DJR45
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To compare: (i) rate of arteriovenous fistula (AVF) interventions in both incident and prevalent end-stage kidney disease patients; (ii) their associated costs; and (iii) intervention-free survival between patients with surgical hemodialysis arteriovenous fistula (SAVF) versus those with an endovascularly created fistula (endoAVF). Materials and Methods: Data from the United States Renal Data System (USRDS) were abstracted to determine the rate of AVF interventions performed in the first year and associated costs (based on Medicare payment rates) for SAVFs created from 2011 to 2013 in the incident and prevalent patient cohorts. Comparative data for endoAVF were obtained from the Novel Endovascular Access Trial (NEAT). Event rates, intervention-free survival, and costs were compared between endoAVF and SAVF cohorts after 1:1 propensity score (PS) matching. Results: In the matched incident patients, the event rate was 0.74 per patient-year (PY) for endoAVF versus 7.22/PY for SAVF (P < .0001), with a difference in expenditures of $16,494. Similarly, in matched prevalent patients the event rate was 0.46/PY for endoAVF vs 4.10/PY for SAVF (P <.0001), resulting in a cost difference of $13,389. Time-to-event analysis showed that at 1 year, 70% of endoAVF patients experienced freedom from intervention versus only 18% of SAVF patients for incident patients; these numbers were 62% and 18% for endoAVF and SAVF prevalent patients, respectively (P < .0001 for both). Conclusions: Both incident and prevalent patients with endoAVF required fewer interventions and had lower costs within the first year compared with matched patients with SAVF.

  • Course Code
    AVIR-DJR46
    Available Until
    6/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To assess biopsy technique, technical success rate, and diagnostic yield of image-guided percutaneous biopsy of omental and
    mesenteric lesions.
    Materials and Methods: This retrospective study included 186 patients (89 men, 97 women; mean [SD] age, 63 [13.8] y) who
    underwent percutaneous image-guided biopsy of omentum and mesentery between March 2007 and August 2015. Biopsies were
    performed with computed tomography (CT) (n 1⁄4 172) or ultrasound (US) (n 1⁄4 14) guidance using coaxial technique yielding core and
    fine-needle aspiration (FNA) specimens. Biopsy results were classified as diagnostic (neoplastic or nonneoplastic) or nondiagnostic
    based on histopathology and cytology. Technical success rate and diagnostic yield of omental and mesenteric lesions were calculated.
    Results: There were 186 image-guided percutaneous biopsies of omental (n 1⁄4 95) and mesenteric (n 1⁄4 91) lesions performed. Technical
    success rate was 99.5% for all biopsies, 100% for omental biopsies, and 98.9% for mesenteric biopsies. Overall sensitivity was 95.5%,
    specificity was 100%, negative predictive value was 78.3%, and positive predictive value was 100%, which was comparable for omental
    and mesenteric biopsies. Core biopsies had higher diagnostic yields compared with FNA: 98.4% versus 84% overall, 99% versus 88% for
    omental biopsies, and 97.7% versus 80% for mesenteric biopsies. Spearman rank correlation showed no correlation between lesion size
    and diagnostic yield (P 1⁄4 .14) and lesion depth and diagnostic yield (P 1⁄4 .29) for both groups. There were 5 complications.
    Conclusions: Image-guided percutaneous omental and mesenteric biopsies have high technical success rates and diagnostic yield
    regardless of lesion size or depth from the skin for both omental and mesenteric specimens.

  • Course Code
    AVIR-DJR47
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To characterize the utility of monitoring transcranial electrical motor evoked potentials (TCeMEPs) and somatosensory evoked potentials (SSEPs) for neural thermoprotection during musculoskeletal tumor ablations. Materials and Methods: Retrospective review of 29 patients (16 male; median age, 46 y; range, 7–77 y) who underwent musculoskeletal tumor radiofrequency ablation (n ¼ 8) or cryoablation (n ¼ 22) with intraprocedural TCeMEP and SSEP monitoring was performed. The most common tumor histologies were osteoid osteoma (n ¼ 6), venous malformation (n ¼ 5), sarcoma (n ¼ 5), renal cell carcinoma (n ¼ 4), and non–small-cell lung cancer (n ¼ 3). The most common tumor sites were spine (n ¼ 22) and lower extremities (n ¼ 4). Abnormal TCeMEP change was defined by 100-V increase above baseline threshold activation for a given myotome; abnormal SSEP change was defined by 60% reduction in baseline amplitude and/or 10% increase in latency. Results: Abnormal changes in TCeMEP (n ¼ 9; 30%) and/or SSEP (n ¼ 5; 17%) occurred in 12 procedures (40%) and did not recover in 5 patients. Patients with unchanged TCeMEP/SSEP activities throughout the procedure (n ¼ 18) did not have motor or sensory symptoms after the procedure; 3 (60%) with unrecovered activity changes and 2 (29%) with transient activity changes had new motor (n ¼ 1) or sensory (n ¼ 4) symptoms. Relative risk for neurologic sequelae for patients with unrecovered TCeMEP/SSEP changes vs those with transient or no changes was 7.50 (95% confidence interval, 1.66–33.9; P ¼ .009). Conclusions: Abnormal activity changes of TCeMEP or SSEP during percutaneous ablative procedures correlate with postprocedural neurologic sequelae. 

  • Course Code
    AVIR-DJR48
    Available Until
    5/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To report initial experience with safety and efficacy in the treatment of pulmonary embolism (PE) using the FlowTriever
    device.
    Materials and Methods: A single-center retrospective study was performed in all patients with acute central PE treated using the
    FlowTriever device between March 2018 and March 2019. A total of 46 patients were identified (massive 1⁄4 8; submassive 1⁄4 38), all

    with right ventricular (RV) strain and 26% with thrombolytic contraindications. Technical success (according to SIR reporting guide-
    lines) and clinical success (defined as mean pulmonary artery pressure intraprocedural improvement) are reported, as are major device

    and procedure-related complications within 30 days after discharge.
    Results: Technical success was achieved in 100% of cases (n 1⁄4 46). Average mean pulmonary artery pressure improved significantly
    from before to after the procedure for the total population (33.9 ± 8.9 mm Hg before, 27.0 ± 9.0 mm Hg after; P < .0001; 95%
    confidence interval [CI], 5.0–8.8), submassive cohort (34.7 ± 9.1 mm Hg before, 27.4 ± 9.2 mm Hg after; P <.0001; 95% CI, 5.2–9.5)
    and massive cohort (30.4 ± 6.9 mm Hg before, 25.4 ± 8.2 mm Hg after; P < .05; 95% CI:0.4–9.6). Intraprocedural reduction in mean
    pulmonary artery pressure was achieved in 88% (n 1⁄4 37 of 42). A total of 100% of patients (n 1⁄4 46 of 46) survived to hospital
    discharge. In total, 71% of patients (n 1⁄4 27 of 38) experienced intraprocedural reduction in supplemental oxygen requirements. Two
    major adverse events (4.6%) included hemoptysis requiring intubation, and procedure-related blood loss requiring transfusion. No
    delayed procedure-related complications or deaths occurred within 30 days of hospital discharge.
    Conclusions: Initial clinical experience using the FlowTriever to perform mechanical thrombectomy showed encouraging trends with
    respect to safety and efficacy for the treatment of acute central, massive, and submassive pulmonary embolism.

  • Course Code
    AVIR-DJR49
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To evaluate the efficacy and safety of embolization of hyperemic synovial tissue for the treatment of knee pain secondary to
    osteoarthritis (OA).
    Materials and Methods: Twenty patients with radiographic knee OA and moderate-to-severe pain refractory to conservative therapy
    were enrolled in a prospective, 2-site pilot study. Genicular artery embolization (GAE) was performed with 75- or 100-μm spherical
    particles. Patients were assessed with magnetic resonance imaging at baseline and at 1 month and with the Visual Analogue Scale (VAS)
    and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and at 1, 3, and 6 months. Adverse
    events were recorded at all timepoints.
    Results: Embolization of at least 1 genicular artery was achieved in 20/20 (100%) patients. Mean VAS improved from 76 mm ± 14 at
    baseline to 29 mm ± 27 at 6-month follow-up (P <.01). Mean WOMAC score improved from 61 ± 12 at baseline to 29 ± 27 at 6-month
    follow-up (P < .01). Self-limiting skin discoloration occurred in 13/20 (65%) patients. Two of 20 (10%) patients developed plantar
    sensory paresthesia that resolved within 14 days.

    Conclusions: GAE to treat knee pain secondary to OA can be performed safely and demonstrates potential efficacy. Further ran-
    domized comparative studies are needed to determine true treatment effect versus placebo effect.

  • Course Code
    AVIR-DJR50
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Structured Education: 

    RA - 2017 Patient Care - Patient Interactions and Management

    0.50

    RA - 2018 Patient Care - Patient Management

    0.50

    VI - 2016 Patient Care - Patient Interactions and Management

    0.50

    VI - 2017 Patient Care - Patient Interactions and Management

    0.50

    RA - 2017 Procedures - Musculoskeletal and Endocrine Sections

    0.50

    RA - 2018 Procedures - Musculoskeletal and Endocrine Sections

    0.50

    VI - 2016 Procedures - Abdominal Angiography and Intervention, GU and GI Nonvascular Procedures

    0.50

    VI - 2017 Procedures - Vascular Diagnostic Procedures

    0.50

  • Course Code
    AVIR-DJR51
    Available Until
    8/1/2022
    Course Type
    Directed Journal Readings
    CEUs
    1.00

    Purpose: To establish a nomogram for predicting the occurrence of early biliary infection (EBI) after percutaneous transhepatic biliary
    stent (PTBS) placement in malignant biliary obstruction (MBO).
    Materials and Methods: In this multicenter study, patients treated with PTBS for MBO were allocated to a training cohort or a
    validation cohort. The independent risk factors for EBI selected by multivariate analyses in the training cohort were used to develop a
    predictive nomogram. An artificial neural network was applied to assess the importance of these factors in predicting EBI. The predictive
    accuracy of this nomogram was determined by concordance index (c-index) and a calibration plot, both internally and externally.
    Results: A total of 243 patients (training cohort: n 1⁄4 182; validation cohort: n 1⁄4 61) were included in this study. The independent risk
    factors were length of obstruction (odds ratio [OR], 1.061; 95% confidence interval [CI], 1.013–1.111; P 1⁄4 .012), diabetes (OR, 5.070;
    95% CI, 1.917–13.412; P 1⁄4 .001), location of obstruction (OR, 2.283; 95% CI, 1.012–5.149; P 1⁄4 .047), and previous surgical or
    endoscopic intervention (OR, 3.968; 95% CI, 1.709–9.217; P 1⁄4 .001), which were selected into the nomogram. The c-index values
    showed good predictive performance in the training and validation cohorts (0.792 and 0.802, respectively). The optimum cutoff value of
    risk was 0.25.
    Conclusions: The nomogram can facilitate the early and accurate prediction of EBI in patients with MBO who underwent PTBS.
    Patients with high risk (> 0.25) should be administered more effective prophylactic antibiotics and undergo closer monitoring.

    NMT - 2017 Procedures

    Gastrointestinal and Genitourinary Procedures

    0.50

    PTH - 2019 Procedures

    Treatment Sites

    0.25

    RA - 2017 Procedures

    Abdominal Section

    1.00

    RA - 2018 Procedures

    Abdominal Section

    1.00

    SON - 2016 Procedures

    Abdominal and Transplant Vasculature

    0.50

    SON - 2019 Procedures

    Abdomen

    0.50

    THR - 2017 Procedures

    Treatment Sites and Tumors

    0.25

    VI - 2016 Procedures

    Abdominal Angiography and Intervention, GU and GI Nonvascular Procedures

    1.00

    VI - 2017 Procedures

    Nonvascular Procedures

Miscellaneous Courses
  • Course Code
    VI-2018
    Available Until
    4/20/2022
    Course Type
    VI Review Course
    CEUs
    4.00

    The AVIR is pleased to announce that our Annual VI Board Prep course, offered at our annual meeting each year, is now available as an online webinar.

    This second edition of the VI Review Course was created for the 2018 annual meeting and includes 4 hours of lectures from new speakers and reviews all of the sections of the ARRT exam matrix. This package also includes AVIR's proprietary mock registry exam and answer sheet to prepare for your test. Both the lecture and the exam can be watched and practiced as many times as you would like, but you must complete the post lecture quiz to recieve CE credits for you time. 

    This course is approved for 4 CE credits.